<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 20, 1998
-------------------
LXR BIOTECHNOLOGY INC.
- --------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 1-12968 68-0282856
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
1401 MARINA WAY SOUTH, RICHMOND, CALIFORNIA 94804
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (510) 412-9100
--------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
1
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS
On April 22, 1998, LXR Biotechnology Inc. (the "Company") issued a press
release, a copy of which is attached herein as Exhibit 99.1, relating to certain
changes in the Company's management.
2
<PAGE> 3
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1 Press Release Issued by the Company on April 22, 1998.
3
<PAGE> 4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LXR BIOTECHNOLOGY INC.
Date: April 28, 1998 By: /s/ G. Kirk Raab
-----------------------------------------------
G. Kirk Raab, Interim Chief Executive Officer
4
<PAGE> 5
EXHIBIT INDEX
Exhibit
- -------
99.1 Press Release Issued by the Company on April 22, 1998
5
<PAGE> 1
EXHIBIT 99.1
Contact: Shelli Geer, Chief Financial Officer
Leah Wong, Corporate Communications
LXR Biotechnology, Inc.
510.412.9100
LXR BIOTECHNOLOGY INC. NAMES G. KIRK RAAB
CHAIRMAN AND INTERIM CHIEF EXECUTIVE OFFICER
Richmond, Calif. - April 22, 1998 -- LXR Biotechnology (AMEX:LXR), is
pleased to announce the appointment of G. Kirk Raab to the position of Chairman
of the Board of Directors and interim Chief Executive Officer. Mr. Raab has been
a director since February 1998. Dr. L. David Tomei, a co-founder of the Company,
has been appointed Executive Vice President and Chief Scientific Officer and
shall remain a director. Dr. Tomei served as Chairman and Chief Executive
Officer since November 1995, and has been a director since January 1996.
"I am pleased that Kirk Raab has accepted the position as Chairman and
interim Chief Executive Officer," said Dr. L. David Tomei, executive vice
president and chief scientific officer of LXR. "My new role as LXR's Executive
Vice President and Chief Scientific Officer affords me the opportunity to
refocus on science and work with a luminary to bring LXR to a new level in the
biopharmaceutical arena."
"LXR's products and science offer a significant opportunity for our
shareholders, employees and future patients. I look forward to working with the
LXR team, particularly David Tomei, to insure this opportunity is achieved,"
said Kirk Raab.
LXR Biotechnology Inc. is a biopharmaceutical company engaged in research
and development of innovative therapeutics designed to treat diseases through
the control of apoptosis or gene-directed cell death. LXR's compounds include
HK-Cardiosol(TM), a heart protectant solution for heart transplantation;
CP-Cardiosol(TM), a cardioplegia solution for heart/lung bypass surgery; and
Elirex(TM) for heart attack.
Statements in this press release that are not historical are forward
looking statements. These forward looking statements are subject to certain
risks and uncertainties that could cause actual results to differ materially
from those anticipated in any forward looking statements, all of which are
difficult to predict and many of which are beyond the control of the Company,
which are detailed in the company's periodic reports and registration statements
filed with the Securities and Exchange Commission. LXR does not undertake to
revise or update any forward looking statements to reflect events or
circumstances that may arise after the date hereof.
For more information, visit LXR Biotechnology's web site at http:\\www.lxr.com
6
